LAG3 and colorectal carcinoma: One study found that blocking both LAG-3 and PD-1 promoted T cell-mediated immune responses leading to a significant delay in tumor growth compared to anti-PD-1 antibody or anti-LAG-3 (LBL-007) treatment alone in CRC model mice.